Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Oxford Biomedica plc    OXB   GB00BDFBVT43

OXFORD BIOMEDICA PLC

(OXB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Oxford Biomedica : notes interim results from AstraZeneca on AZD1222 showing strong antibody and T-cell responses and acceptable safety profile

share with twitter share with LinkedIn share with facebook
07/20/2020 | 12:01pm EDT

Oxford, UK - 20 July, 2020: Oxford Biomedica plc (LSE:OXB) ('Oxford Biomedica' or 'the Group'), a leading gene and cell therapy group, notes that AstraZeneca UK Ltd ('AstraZeneca') has announced interim results from the ongoing Phase I/II COV001 trial, led by Oxford University on AZD1222 which showed the SARS-CoV-2 vaccine candidate AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.

COV001 is a blinded, multi-centre, randomised controlled Phase I/II trial with 1,077 healthy adult participants, aged 18-55 years. It assessed a single dose of AZD1222 against a comparator meningococcal conjugate vaccine, MenACWY. Ten participants also received two doses of AZD1222 one month apart.

The results published in The Lancet confirmed a single dose of AZD1222 resulted in a four-fold increase in antibodies to the SARS-CoV-2 virus spike protein in 95% of participants one month after injection. In all participants, a T-cell response was induced, peaking by day 14, and maintained two months after injection.

Neutralising activity against SARS-CoV-2 (as assessed by the MNA80 assay) was seen in 91% of participants one month after vaccination and in 100% of participants who received a second dose. The levels of neutralising antibodies seen in participants receiving either one or two doses were in a similar range to those seen in convalescent COVID-19 patients. Strong correlations were observed across neutralisation assays.

To view the full announcement from AstraZeneca please follow this link

As announced on 28 May 2020, Oxford Biomedica has signed a one year Clinical & Commercial Supply Agreement with AstraZeneca who will have access to Oxford Biomedica's new 7,800 m2 commercial manufacturing centre Oxbox, located in Oxford, UK. The initial agreement requires Oxford Biomedica to provide AstraZeneca with multiple batches of vaccine, the majority of which are expected to be produced throughout 2020. The production will be from one of the Group's recently approved GMP suites in Oxbox.

-Ends-

Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer, T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer, T: +44 (0)1865 783 000
Catherine Isted, Head of Corporate Development & IR, T: +44 (0)1865 954 161 / E: ir@oxb.com

Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal, T: +44 (0)20 3709 570

About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the 'Group') have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available at http://www.oxb.com/

About Oxbox
Oxbox is Oxford Biomedica's new 7,800 m2 commercial manufacturing centre, located in Oxford, UK. Phase I, which will be operational in 2020, is 4,200 m2 of developed area consisting of six Good Manufacturing Practices ('GMP') clean room suites - four for vector production and two for fill-finish, warehousing and cold chain facilities and support laboratories. The Company received MHRA approval for the first two suites in Oxbox in May this year. Phase II will provide for flexible expansion for a further six GMP clean room suites. This world class facility is expected to more than double Oxford Biomedica's manufacturing capacity, supporting further growth in revenues.

Disclaimer

Oxford BioMedica plc published this content on 20 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 July 2020 16:00:16 UTC

share with twitter share with LinkedIn share with facebook
Latest news on OXFORD BIOMEDICA PLC
08/03OXFORD BIOMEDICA : Summary Toggle Axovant Signs Three-Year Clinical Supply Agree..
AQ
08/03OXFORD BIOMEDICA : Signs Development, Manufacture & License Agreement with Beam ..
PU
07/31OXFORD BIOMEDICA : Signs Three Year Clinical Supply Agreement with Axovant Gene ..
PU
07/20OXFORD BIOMEDICA : notes interim results from AstraZeneca on AZD1222 showing str..
PU
06/24ANNUAL GENERAL MEETING : Questions and Answers
PU
06/23OXFORD BIOMEDICA : Annual General Meeting
PU
06/19OXFORD BIOMEDICA : Information in Relation to Annual General Meeting
PU
06/13OXFORD BIOMEDICA : AstraZeneca to deliver Oxford-developed COVID-19 vaccine once..
AQ
06/08UK stocks end lower on concerns over corporate debt; AstraZeneca weighs
RE
06/08Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Ma..
GL
More news
Financials
Sales 2020 77,9 M 102 M 102 M
Net income 2020 -5,23 M -6,84 M -6,84 M
Net cash 2020 18,1 M 23,7 M 23,7 M
P/E ratio 2020 -127x
Yield 2020 -
Capitalization 687 M 899 M 899 M
EV / Sales 2020 8,59x
EV / Sales 2021 6,44x
Nbr of Employees 555
Free-Float 83,3%
Chart OXFORD BIOMEDICA PLC
Duration : Period :
Oxford Biomedica plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OXFORD BIOMEDICA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 988,88 GBX
Last Close Price 850,00 GBX
Spread / Highest target 70,6%
Spread / Average Target 16,3%
Spread / Lowest Target -32,5%
EPS Revisions
Managers
NameTitle
John Andrew Dawson Chief Executive Officer & Executive Director
Frederic Roch Doliveux Non-Executive Chairman
Nick Page Chief Operating Officer
Stuart Paynter Chief Financial Officer & Director
Kyriacos Mitrophanous Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
OXFORD BIOMEDICA PLC31.78%911
GILEAD SCIENCES, INC.6.73%86 946
VERTEX PHARMACEUTICALS24.68%71 105
REGENERON PHARMACEUTICALS65.18%65 265
WUXI APPTEC CO., LTD.72.04%38 070
GENMAB A/S55.18%23 785